Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients
Merit Medical Systems (NASDAQ: MMSI) announced positive 6-month results from the randomized arteriovenous (AV) fistula arm of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The study, involving 245 patients at 43 sites, compared WRAPSODY, a cell-impermeable endoprosthesis, to percutaneous transluminal angioplasty (PTA) for maintaining blood flow in dialysis patients' AV fistulas.
Key findings include:
- WRAPSODY achieved 89.8% target lesion primary patency at 6 months, compared to 62.8% for PTA (p<0.0001)
- Similar adverse event rates between WRAPSODY and PTA groups
- Results support WRAPSODY as a potential new standard of care for AV fistula patients
The data, presented at CIRSE 2024, will support Merit Medical's Premarket Approval application to the FDA for commercial use in the United States.
Merit Medical Systems (NASDAQ: MMSI) ha annunciato risultati positivi a 6 mesi dal braccio randomizzato della fistola arteriovenosa (AV) del suo studio clinico WRAPSODY Arteriovenous Access Efficacy (WAVE). Lo studio, che ha coinvolto 245 pazienti in 43 sedi, ha confrontato WRAPSODY, un endoprotesi impermeabile alle cellule, con l'angioplastica transluminale percutanea (PTA) per il mantenimento del flusso sanguigno nelle fistole AV dei pazienti in dialisi.
I principali risultati includono:
- WRAPSODY ha raggiunto una patenza primaria della lesione target del 89,8% a 6 mesi, rispetto al 62,8% per PTA (p<0,0001)
- Le tariffe di eventi avversi sono simili tra i gruppi WRAPSODY e PTA
- I risultati supportano WRAPSODY come un potenziale nuovo standard di cura per i pazienti con fistola AV
I dati, presentati al CIRSE 2024, supporteranno la domanda di approvazione pre-commerciale di Merit Medical presso la FDA per l'uso commerciale negli Stati Uniti.
Merit Medical Systems (NASDAQ: MMSI) anunció resultados positivos a 6 meses del brazo aleatorizado de fístula arteriovenosa (AV) de su ensayo pivotal WRAPSODY Arteriovenous Access Efficacy (WAVE). El estudio, que involucró a 245 pacientes en 43 sitios, comparó WRAPSODY, un endoprótesis impermeable a las células, con la angioplastia transluminal percutánea (PTA) para mantener el flujo sanguíneo en las fístulas AV de los pacientes en diálisis.
Los resultados clave incluyen:
- WRAPSODY logró una patente primaria de lesión objetivo del 89.8% a los 6 meses, en comparación con el 62.8% para PTA (p<0.0001)
- Tasas similares de eventos adversos entre los grupos WRAPSODY y PTA
- Los resultados respaldan a WRAPSODY como un nuevo estándar potencial de atención para los pacientes con fístula AV
Los datos, presentados en CIRSE 2024, apoyarán la solicitud de aprobación previa al mercado de Merit Medical a la FDA para su uso comercial en los Estados Unidos.
Merit Medical Systems (NASDAQ: MMSI)는 WRAPSODY 혈관 접근 효능(WAVE) 주요 시험의 정맥루(AV) 주Arm에서의 6개월 긍정적 결과를 발표했습니다. 43개 장소에서 245명의 환자가 참여한 이 연구에서는 세포 침투가 불가능한 내장형 인공혈관 WRAPSODY와 경피적 혈관 성형술(PTA)을 비교하여 투석 환자의 AV 정맥루에서의 혈류 유지를 평가하였습니다.
주요 결과는 다음과 같습니다:
- WRAPSODY는 6개월 동안 목표 병변의 1차 개통성을 89.8% 달성하였고, PTA는 62.8%였습니다 (p<0.0001)
- WRAPSODY와 PTA 그룹 간의 유사한 부작용 발생률
- 결과는 AV 정맥루 환자를 위한 잠재적인 새로운 표준 치료법으로 WRAPSODY를 지지합니다
CIRSE 2024에서 발표된 이 데이터는 미국에서 상업 사용을 위한 Merit Medical의 사전 시장 승인 신청을 지원할 것입니다.
Merit Medical Systems (NASDAQ: MMSI) a annoncé des résultats positifs à 6 mois du bras randomisé de la fistule artérioveineuse (AV) de son essai pivot WRAPSODY Arteriovenous Access Efficacy (WAVE). L'étude, impliquant 245 patients dans 43 sites, a comparé WRAPSODY, une endoprothèse imperméable aux cellules, à l'angioplastie transluminale percutanée (PTA) pour le maintien du flux sanguin dans les fistules AV des patients sous dialyse.
Les principaux résultats comprennent :
- WRAPSODY a atteint 89,8 % de perméabilité primaire de la lésion cible à 6 mois, contre 62,8 % pour la PTA (p<0,0001)
- Taux d'événements indésirables similaires entre les groupes WRAPSODY et PTA
- Les résultats soutiennent WRAPSODY en tant que nouveau standard potentiel de soins pour les patients atteints de fistule AV
Les données, présentées à CIRSE 2024, soutiendront la demande d'approbation préalable à la mise sur le marché de Merit Medical auprès de la FDA pour un usage commercial aux États-Unis.
Merit Medical Systems (NASDAQ: MMSI) hat positive 6-Monats-Ergebnisse aus dem randomisierten Arteriovenösen (AV) Fistelarm seiner WRAPSODY Arteriovenous Access Efficacy (WAVE) Hauptstudie bekannt gegeben. Die Studie, die 245 Patienten an 43 Standorten umfasste, verglich WRAPSODY, ein zellimpermeables Endoprothese, mit der perkutanen transluminalen Angioplastie (PTA) zur Aufrechterhaltung des Blutflusses in den AV-Fisteln von Dialysepatienten.
Wichtige Ergebnisse sind:
- WRAPSODY erreichte eine primäre Patency der Zielläsion von 89,8 % nach 6 Monaten im Vergleich zu 62,8 % für PTA (p<0,0001)
- Ähnliche Raten von unerwünschten Ereignissen zwischen den WRAPSODY- und PTA-Gruppen
- Die Ergebnisse unterstützen WRAPSODY als potenziellen neuen Standard der Versorgung für AV-Fistelpatienten
Die Daten, die auf der CIRSE 2024 vorgestellt wurden, werden den Antrag von Merit Medical auf Vorabgenehmigung bei der FDA für die kommerzielle Nutzung in den Vereinigten Staaten unterstützen.
- WRAPSODY showed 27 percentage points higher target lesion primary patency compared to PTA (89.8% vs. 62.8%, p<0.0001)
- Similar adverse event rates between WRAPSODY and PTA groups, indicating comparable safety profile
- Positive results support potential FDA approval and commercial launch in the US market
- WRAPSODY is already available in Brazil and the European Union, indicating existing market presence
- None.
Insights
The WRAPSODY WAVE trial results are highly impactful for Merit Medical Systems and the dialysis industry. The 89.8% target lesion primary patency at 6 months for WRAPSODY compared to 62.8% for standard percutaneous transluminal angioplasty (PTA) is a significant clinical improvement. This
The potential of WRAPSODY to become the new standard of care for maintaining AV fistula patency in dialysis patients could lead to reduced interventions, improved patient outcomes and lower healthcare costs. This breakthrough could position Merit Medical as a market leader in dialysis access management, potentially driving substantial revenue growth.
However, it's important to note that WRAPSODY is not yet FDA-approved. The positive trial results support the ongoing Premarket Approval (PMA) application, but regulatory hurdles remain before commercialization in the US market.
This clinical trial success is a significant positive catalyst for Merit Medical Systems (NASDAQ: MMSI). The WRAPSODY device shows strong potential to disrupt the dialysis market, which could translate into substantial revenue growth for the company.
While specific financial projections aren't provided, the dialysis market is large and growing. With over 2 million people worldwide receiving hemodialysis, a superior product for maintaining vascular access could capture significant market share. Investors should monitor for:
- FDA approval timeline and potential launch date
- Pricing strategy and reimbursement prospects
- Production capacity and scalability
- Potential partnerships or licensing deals
The positive clinical data reduces regulatory risk, but commercialization challenges remain. Overall, this news likely positions Merit Medical for long-term growth in a critical healthcare segment.
In the US pivotal trial, WRAPSODY achieved
SOUTH JORDAN, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced positive 6-month findings from the randomized arteriovenous (AV) fistula arm of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The data were shown at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) during a FIRST@CIRSE presentation.
WRAPSODY is a cell-impermeable endoprosthesis which is intended to extend long-term vessel patency in dialysis patients. Many patients undergoing dialysis rely on a vascular access site created in the arm called an AV fistula. The maintenance of adequate blood flow through this site is crucial for patient survival.
The AV fistula arm of the WAVE trial enrolled 245 patients at 43 sites. Patients were randomized 1:1 to WRAPSODY or percutaneous transluminal angioplasty (PTA). Target lesion primary patency in patients treated with WRAPSODY was 27 percentage points higher than patients in the PTA cohort (
“The superiority of the six-month efficacy data is compelling and provides clinicians the chance to evaluate how WRAPSODY can help us prolong the vascular access of our patients. WRAPSODY should be the new standard of care for these patients,” said Mahmood K. Razavi, MD, FSIR, FSVM, Interventional Radiologist and Medical Director of Clinical Research at St. Joseph Heart and Vascular Center in Orange, Calif., and Co-Principal Investigator of the WAVE trial. “Meeting with colleagues at CIRSE to discuss the AV fistula arm of the WAVE study was the first of what we hope to be many productive discussions,” said Robert G. Jones, FRCR, Consultant Interventional Radiologist at Queen Elizabeth Hospital Birmingham in Birmingham, England, and Co-Principal Investigator of the WAVE study. “The potential for WRAPSODY to help us safely extend vascular access for our patients is a vital component of care.”
“The data release of positive findings from the randomized AV fistula arm of the WAVE study marks a major milestone for Merit,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “This is an important next step in our continued efforts to seek ways to improve care for patients requiring hemodialysis treatment.”
The Merit WRAPSODY Cell-Impermeable Endoprosthesis is not approved or available for commercial distribution in the United States and may not be approved or available for sale or use in other countries. In the United States, the device is being used under an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA). Findings from the WAVE study expand on results from the first-in-human study (WRAPSODY FIRST) and support the Premarket Approval (PMA) application to the FDA for commercial use in the United States. The device is available in Brazil and in the European Union. For additional information on Merit Medical’s WAVE study, please visit: https://clinicaltrials.gov/ct2/show/NCT04540302.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Statements contained in this release which are not purely historical, including, without limitation, statements regarding results, outcomes and applications of clinical trials, studies and investigations involving Merit’s products, safety, efficacy and patient and physician adoption of Merit’s products, Merit’s ability to procure and maintain required regulatory approvals for its products, forecasted plans, revenues and other operating and financial measures, or future growth and profit expectations or forecasted economic conditions, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to risks and uncertainties such as those described in Merit’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”) and other filings with the SEC. Such risks and uncertainties include inherent risks and uncertainties related to the safety, efficacy and patient and physician adoption of Merit’s products, the ability to fully enroll and the final results and outcomes of clinical trials and studies involving the Merit’s products, the ability to obtain and maintain reimbursement codes for Merit’s products, Merit’s ability to procure and maintain required regulatory approvals for its products, disruptions in Merit’s supply chain, manufacturing or sterilization processes; reduced availability of, and price increases associated with, commodity components and other raw materials; adverse changes in freight, shipping and transportation expenses; negative changes in economic and industry conditions in the United States or other countries, including inflation; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; risks associated with Merit’s ongoing or prospective manufacturing transfers and facility consolidations; fluctuations in interest or foreign currency exchange rates; risks and uncertainties associated with Merit’s information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; consequences associated with a Corporate Integrity Agreement executed between Merit and the U.S. Office of Inspector General – Department of Health and Human Services; difficulties, delays and expenditures relating to development, testing and regulatory approval or clearance of Merit’s products, including the pursuit of approvals under the European Union Medical Device Regulation, and risks that such products may not be developed successfully or approved for commercial use; litigation and other judicial proceedings affecting Merit; the potential of fines, penalties or other adverse consequences if Merit’s employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the assertion that Merit’s technology infringes the rights of other parties; product recalls and product liability claims; changes in customer purchasing patterns or the mix of products Merit sells; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations, including reforms to the procedures for approval or clearance of Merit’s products by the U.S. Food & Drug Administration or comparable regulatory authorities in other jurisdictions; changes in tax laws and regulations in the United States or other jurisdictions; termination of relationships with Merit’s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit’s existing or future products obsolete; market acceptance of new products; dependance on distributors to commercialize Merit’s products in various jurisdictions outside the United States; volatility in the market price of Merit’s common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; failure to introduce products in a timely fashion; price and product competition; fluctuations in and obsolescence of inventory; and other factors referenced in the 2023 Annual Report and other materials filed with the SEC.
All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.
ABOUT MERIT MEDICAL
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com
Investor Inquiries
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@westwicke.com
1 The primary efficacy endpoint was defined as the freedom from clinically driven target lesion revascularization or target lesion thrombosis through 6 months.
2 The primary safety endpoint was the proportion of patients who experienced an adverse event in the 30 days following treatment that negatively affected the access or venous outflow circuit and resulted in reintervention, hospitalization, or death (not including stenosis or thrombosis).
FAQ
What were the key results of Merit Medical's WRAPSODY WAVE trial for AV fistula patients?
How many patients and sites were involved in the WRAPSODY WAVE trial for Merit Medical (MMSI)?
Is Merit Medical's WRAPSODY device currently approved for use in the United States?
Where is Merit Medical's WRAPSODY device currently available for use?
